🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 8 of 116

  1. Dostarlimab

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  2. Doxorubicin

    Takeda

    Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. Doxorubicin 2 mg/ml Solution for Injection., Fibromun

    Philogen S.p.A.

    Unresectable or metastatic soft tissue sarcoma

    phase 3 small molecule active

    1 trial

  4. Doxorubicine + docetaxel sequential

    Sanofi Pasteur

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  6. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  7. Durvalumab

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  8. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  9. Durvalumab

    AstraZeneca

    Non Small Cell Lung Cancer NSCLC

    phase 3 small molecule active

    1 trial

  10. Durvalumab

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  11. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  12. Durvalumab

    AstraZeneca

    Locally Advanced Cervical Cancer

    phase 3 mab completed

    1 trial

  13. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. Durvalumab

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  16. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  17. E7777 9 mcg/kg

    CITIUS ONCOLOGY, INC.

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  18. EADM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  19. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  20. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  21. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  22. ELOXATINE 5 mg/ml, solution à diluer pour perfusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  23. ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  24. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  25. ERYTHROPOIETIN , Elritercept

    Takeda

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  26. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  27. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  28. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  29. ETOPOSIDE, PACLITAXEL, IFOSFAMIDE, CISPLATIN, CARBOPLATIN

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  30. EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

    Pfizer Australia Pty Ltd

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  31. Elective nodal irradiation (ENI)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 3 other active

    1 trial

  32. Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial

  33. Endoscopic submucosal dissection

    Chinese University of Hong Kong

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  34. Endoscopic submucosal dissection

    United Therapeutics Europe Ltd

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  35. Endostar

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  36. Enzalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone Sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  37. Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  38. Epinephrine

    Chinese University of Hong Kong

    Gastric Neoplasm

    phase 3 small molecule completed

    1 trial

  39. Epirubicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  40. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  41. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  42. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  43. Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  44. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  45. Etoposide

    The First People's Hospital of Lianyungang

    Non-Hodgkin's Lymphoma

    phase 3 small molecule active

    1 trial

  46. Everolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  47. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  48. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.